Previous 10 | Next 10 |
BofA Securities has downgraded Organon ( NYSE: OGN ) to neutral from buy following the company's recent Q2 2022 results as there are better opportunities for upside in pharma. The firm also lowered its price target to $37 from $40 (~14% upside based on Thursday's close...
Organon & Co. (OGN) Q2 2022 Earnings Conference Call August 4, 2022 08:30 ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Sandra Milligan - Head, R&...
The following slide deck was published by Organon & Co. in conjunction with their 2022 Q2 earnings call. For further details see: Organon & Co. 2022 Q2 - Results - Earnings Call Presentation
Despite reporting better than expected financials for 2Q 2022, Organon ( NYSE: OGN ), Merck’s ( MRK ) spinoff focused on women’s health and biosimilars, narrowed the range of 2022 revenue guidance, citing the ongoing unfavorable impact of forex rates. O...
Organon press release ( NYSE: OGN ): Q2 Non-GAAP EPS of $1.25 beats by $0.06 . Revenue of $1.59B (flat Y/Y) beats by $60M . Full year 2022 financial guidance ranges updated: Revenues range narrowed to $6.1 billion to $6.3 billion from a prior outlook o...
Second quarter 2022 revenues of $1,585 million Second quarter diluted earnings per share from continuing operations of $0.92 and non-GAAP adjusted diluted earnings per share from continuing operations of $1.25 Both reported and non-GAAP adjusted diluted earnings per share incl...
Organon ( NYSE: OGN ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $1.19 (-30.8% Y/Y) and the consensus Revenue Estimate is $1.53B (-3.8% Y/Y). Over the last 1 year, OGN has beaten EPS est...
Viatris is down 40% since the spin-off. Financial metrics are positively increasing as one-time costs of the merger are decreasing. Safe and high dividend yield combined with exceptional free cash flow yield offer a great margin of safety. The restructuring of the company offers a...
Teva posted second-quarter results that exceeded market expectations. Teva's outlook looks bright. Opioid settlement another reason the stock added 30% after the earnings report. When Teva Pharmaceutical Industries Limited ( TEVA ) posted second-quarter results, the ...
Women’s healthcare company Organon ( NYSE: OGN ) and life science company Cirqle Biomedical announced a research collaboration and license agreement on Thursday to develop and commercialize an experimental contraceptive candidate. According to pre-clinical data, the...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...